Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

8 Apr 2003

Abstract excerpt

A regimen of busulfan and cyclophosphamide is standard therapy before transplantation of allogeneic hematopoietic stem cells in patients with chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). The clinical trial reported here was undertaken to test the hypothesis that fludarabine can replace cyclophosphamide in this regimen and facilitate donor engraftment with reduced toxicity. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12676781
DOI: 10.1182/blood-2002-11-3567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsPMID 12676781Read ↗

Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Semantic proximity Read ↗

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesSemantic proximity Read ↗

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Semantic proximity Read ↗

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Bone Marrow Transplantation for Fanconi Anemia Using Fludarabine-Based ConditioningSemantic proximity Read ↗

Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell TransplantationSemantic proximity Read ↗

Hemopoietic cell transplantation for the myelodysplastic syndromes.Semantic proximity Read ↗

Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 MutationsSemantic proximity Read ↗

Alternative donor hematopoietic cell transplantation for Fanconi anemiaSemantic proximity Read ↗

Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell DiseaseSemantic proximity Read ↗

Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.